Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series

Table 1

Description of patient initiated on LCIG therapy at our centre.

Patient number	Age at onset of PD; (yrs)	Genetic cause	UPDRS3; Off/On	Age started LCIG; (yrs)	Length of LCIG treatment to date; (months)
1	28		88/30	59	47
2	30		74/37	59	46
3	28	Parkin	62/33	63	3—deceased
4	38		67/43	66	Judged unsuitable during NJ phase
5	48		54/20	67	3—stopped
6	49	LRRK2	78/33	68	24—deceased (Ca colon)
7	48		66/50	72	26
8	45		44/5	63	23
9	44		57/22	66	21
10	58		62/	72	21
11	55		50/30	72	3—stopped
12	43	Parkin	51/31	65	5